Synthesis of modified pyrimidine bases and positive impact of chemically reactive substituents on their in vitro antiproliferative activity

European Journal of Medicinal Chemistry

Volumn 44, Issue 3, 2009, Pages 1172-1179

  Noll, Steffi ^a   Kralj, Marijeta ^b   Šuman, Lidija ^b   Stephan, Holger ^a   Piantanida, Ivo ^b  

^a INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

^b RUDER BO KOVI INSTITUTE   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 5 HYDROXYMETHYLCYTOSINE; 1 METHYL N 4 (4 TOLUENESULFONYL)CYTOSINE; 5 (AMINOACETYL)AMINOURACIL; 5 (CHLOROACETYL)AMINO 1 [(1,3 DIHYDROXY 2 PROPOXY)METHYL]URACIL; 5 (CHLOROACETYLAMINO)URACIL; 5 (N TERT BUTYLOXYCARBONYLETHYLENEDIAMINOACETYL)AMINOURACIL; 5 [BIS [2 (4 METHOXY)BENZYLTHIOETHYL]AMINE]ACETYLAMINOURACIL; [2 [(2,4 DIOXO 1,2,3,4 TETRAHYDROPYRIMIDINE 5 YL) AMINO] 2 OXOETHYL] DEXTRO CYSTEINE; ANTINEOPLASTIC AGENT; FLUOROURACIL; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG SYNTHESIS; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; TUMOR GROWTH;

CELL CYCLE; CELL LINE; CELL PROLIFERATION; HUMANS; PYRIMIDINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 60549092110     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2008.06.002     Document Type: Article

References (21)

1. Sampath D., Rao V.A., and Plunkett W. Oncogene 22 (2003) 9063-9074
2. Longley D.B., Harkin D.P., and Johnston P.G. Nat. Rev. Cancer 3 (2003) 330-338
3. Goulian M., Bleile B.M., Dickey L.M., Grafstrom R.H., Ingraham H.A., Neynaber S.A., Peterson M.S., and Tseng B.Y. Adv. Exp. Med. Biol. 195 (1986) 89-95
4. Gangjee A., Elzein E., Kothare M., and Vasudevan A. Curr. Pharm. Des. 2 (1996) 263-280
5. Berman E.M., and Werbel L.M. J. Med. Chem. 34 (1991) 479-485
6. Jackson R.C. In: Jackman A.L. (Ed). Antifolate Drugs in Cancer Therapy (1999), Humana Press, Totowa 1-12
7. Mukherjee K.L., and Heidelberger C. J. Biol. Chem. 235 (1960) 433-437
8. Malet-Martino M., Jolimaitre P., and Martino R. Curr. Med. Chem. Anti Cancer Agents 2 (2002) 267-310
9. Kazuno H., Shimamoto Y., Tsujimoto H., Fukushima M., Matsuda A., and Sasakio T. Oncol. Rep. 17 (2007) 1453-1460
10. G.H. Hitchings, R.L. Thomson, U.S. Patent 2,494,125, 1950.
11. Corbin J.L., Miller K.F., Pariyadath N., Wherland S., Bruce A.E., and Stiefel E.I. Inorg. Chim. Acta 90 (1984) 41-51
12. Grote M., Noll St., Noll B., Johannsen B., and Kraus W. Can. J. Chem. 82 (2004) 513-523
13. Ulbricht T.L.V., and Price C.C. J. Org. Chem. 21 (1956) 567-571
14. Hosmane R.S., and Leonhard N.J. Synthesis (1981) 118-119
15. Fox J.J., and van Praag D. J. Am. Chem. Soc. 82 (1960) 486-489
16. Delia T.J., Olsen M.J., and Brown G.B. J. Org. Chem. 30 (1965) 2766-2768
17. Žinić B., Krizmanić I., Vikić-Topić D., and Žinić M. Croat. Chem. Acta 74 (1999) 957-966
18. Kašnar B., Krizmanić I., and Žinić M. Nucleosides Nucleotides 16 (1997) 1067-1071
19. Grem J.L. Invest. New Drugs 18 (2000) 299-313
20. Silverman R.B. The Organic Chemistry of Drug Design and Drug Action (2004), Elsevier Academic Press, New York pp. 298-302
21. Hranjec M., Kralj M., Piantanida I., Sedić M., Šuman L., Pavelić K., and Karminski-Zamola G. J. Med. Chem. 50 (2007) 5696-5711